TOP TEN perturbations for 39669_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39669_at
Selected probe(set): 211712_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39669_at (211712_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-4.653013
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)

Relative Expression (log2-ratio):4.5820856
Number of Samples:2 / 3
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS).

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):4.3901625
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):4.1903343
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)

Relative Expression (log2-ratio):4.1658583
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (inflammatory carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma.

split-thickness skin grafting study 1 / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-4.1642056
Number of Samples:6 / 8
Experimental split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-4.1485443
Number of Samples:8 / 18
Experimental esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (cribriform carcinoma; primary)

Relative Expression (log2-ratio):4.075982
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (cribriform carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with cribriform carcinoma.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)

Relative Expression (log2-ratio):3.978881
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).

ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.9091702
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).